Search Results
364 items found for "LASEREDD Therapeutics"
Programs (1)
- Applying Pharmacology to Drug Discovery
What makes each drug type unique to therapeutic pharmacology? 3.
Posts (243)
- Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
July 2022 "I’m happy to share that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics
- Tectonic Therapeutic Strengthens Leadership Team
July 2022 "July 19, 2022 07:00 AM Eastern Daylight Time BOSTON--Tectonic Therapeutic, Inc. a pre-clinical
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
adipose tissue size more effectively than exendin, suggesting that biased agonism can lead to distinct therapeutic In conclusion, biased agonism at the GLP-1R represents a promising strategy for optimizing therapeutic continues to grow, it is likely to play an increasingly important role in the design of next-generation therapeutics Christopoulos, Signalling bias in new drug discovery: detection, quantification and therapeutic impact Drucker, D.J., Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Other Pages (120)
- Noval insights and therapeutic strategies for tumor-induced kidney pathologies
< GPCR News < GPCRs in Oncology and Immunology Noval insights and therapeutic strategies for tumor-induced receptor (TACR3), a homolog of the G protein-coupled receptor TkR99D in fruit flies, as a potential therapeutic The implications of these findings for transforming the therapeutic approaches to renal complications These insights could contribute to the advancement of diagnostic and therapeutic strategies for treating
- CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases
< GPCR News < GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies This review highlights the potential as a therapeutic target of the CCR6 receptor in numerous diseases
- Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer
Sponsors GPCR Retreat Program < Back to schedule Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Several of these targets are being developed for potential new therapeutic strategies in ovarian and